Vega LCA, Ariza AR, Rodríguez WFL

Language: Spanish
References: 33
Page: 158-165
PDF size: 85.58 Kb.

ABSTRACT

Brucellosis is a zoonosis due to genus Brucella which is a negative gram bacillus. It was identified for the first time in the Mexican Republic in 1905 and since then it has been a permanent entity. The Brucellas are classified in six species of which only B. melitensis, B. abortus, B. suis, and B. canis infects the man. The main causes of infection are through the ingestion of unpasteurized milk and by the contact with infected animals. The lipopolysaccharide that is in the membrane of the bacterium it is the major determinant of virulence. The clinical manifestations are non-specific and the brucella can produce located forms in a 30% of the cases. The diagnosis is based on the isolation of the microorganism in cultures of blood and other weaves. Serologically we have some methods like the agglutination in tube and the polymerase chain reaction. The treatment recommended by the World Health Organization is according to three schemes and the best treatment is with aminoglycosides and tetracyclines. The main cause of mortality is endocarditis and meningoencephalitis. The prevention includes principally avoiding the contact with infected animals and the pasteurization of milky products.

REFERENCES

1. Pappas G, Papadimitrou P, Akritidis N, Christou L et al. The new global map of human brucellosis. Lancet Infect Dis 2006; 6: 91-99.

2. Ruiz CM. Introducción histórica. En: Ruiz Castañeda M. Brucelosis. La Prensa Médica Mexicana. México, 1990. 7 ed. 2-13.

3. Laval E. Contribución al estudio histórico de la brucelosis en Chile. Rev Chil Infect 2006; 23(4): 362-66.

4. Pappas G, Akritidis N, Bosilkovski M, Tsianos E. Brucellosis. N Engl J Med 2005; 352: 2325-36.

5. Sistema Único de Información para la Vigilancia Epidemiológica. Casos por entidad federativa de enfermedades zoonóticas hasta la semana epidemiológica 52 del 2007. Dirección General de Epidemiología de la Secretaría de Salud de los Estados Unidos Mexicanos.

6. Sistema único automatizado de vigilancia epidemiológica (SUAVE). Resumen Anual 1990-2000.

7. Sbriglio JL, Sbriglio H, Sainz S. Brucelosis. Revista Bioanálisis 2007: 19-22.

8. Centers for Disease Control and Prevention. Suspected brucellosis case prompts investigation of possible bioterrorism-related activity. MMWR 2000; 49(23): 509-12.

9. Hernández A, García P, Cruz A, Rojo J. Seroprevalencia de brucelosis en disponentes de sangre del Hospital General de México. Rev Med Hosp Gen Mex 1999; 62(2): 107-12.

10. Torres JC, López A, García RM, Gutiérrez JN. Seroprevalencia de anticuerpos anti-Brucella en disponentes de sangre con fines terapéuticos en tres bancos de sangre del Instituto Mexicano del Seguro Social. Gac Méd Méx 2004; 140(4): 391-98.

11. Mantur BG, Amarnath SK, Shinde RS. Review of clinical and laboratory features of human brucellosis. Indian Journal of Medical Microbiology 2007; 25(3): 188-202.

12. Castro HA, González SR, Prat MI. Brucelosis: Una revisión práctica. Acta Bioquím Clín Latinoam 2005; 39(2): 203-16.

13. Rodríguez M, Solera J, Sánchez L, Álvarez M. Brucelosis. Aspectos patogénicos. Clínica, diagnóstico y tratamiento. Formas específicas de la enfermedad. Medicine 1998; 7(79): 3651-3658.

14. Segura JC. Brucelosis. Guías Clínicas 2005; 5(25): 1-6.

15. Tawfiq JA. Therapeutic options for human brucellosis. Expert Rev Anti Infect Ther 2008; 6(1): 109-20.

16. Serra J, Viñas M. Laboratory diagnosis of brucellosis in a rural endemic area in northeastern Spain. Int microbiol 2004; 7: 53-58.

17. Rubio M, del Pozo JL, Hernández JM, Dorronsoro I et al. Diagnóstico de la brucelosis humana. Influencia del pH en la prueba de seroaglutinación y sobre la actividad aglutinante de los anticuerpos IgM, IgG e IgA. Enferm Infecc Microbiol Clin 2002; 20(4): 144-9.

18. Skalsky K, Yahav D, Bishara J, Pitlik S et al. Treatment of human brucellosis: systematic review and meta-analysis of randomized controlled trials. BMJ 2008; 25(1): 1-8.

19. World Health Organization. Brucellosis in humans and animals. WHO/CDS/EPR/2006.7.

20. Norma Oficial Mexicana NOM-022-SSA2-1994. Para la prevención y control de la brucelosis en el hombre.

21. López MA. Vacunas en la brucelosis humana. En: Escobar J.L. Vacunas, ciencia y salud. Secretaría de Salud. México, 1992: 509-20.

22. Estein SM. Brucelosis: inmunidad y vacunación. Revista electrónica de veterinaria 2006; 7(5): 1-25.

23. Rabinowitz P, Gordon Z, Odofin L. Pet-Related infections. Am Fam Physician 2007; 76(9): 1314-22.

24. Norma Oficial Mexicana NOM-041-ZOO-1995. Campaña Nacional contra la Brucelosis en los Animales.

25. Rodríguez ME, Pousa A, Pons C, Larrosa A, Sánchez LP et al. La brucelosis como enfermedad profesional: estudio de un brote de transmisión aérea en un matadero. Rev Esp Salud Pública 2001; 75(2): 159-70.

26. Morata P, Queipo MI, Reguera JM, García MA et al. Development and evaluation of a PCR-enzyme-linked immunoabsorbent assay for diagnosis of human brucellosis. J Clin Microbiol 2003; 41(1): 144-48.

27. Navarro E, Segura JC, Castano MJ, Solera J. Use of real-time quantitative polymerase chain reaction to monitor the evolution of Brucella melitensis DNA load during therapy and post-therapy follow-up in patients with brucellosis. CID 2006; 42(9): 1266-73.

28. Vrioni G, Pappas G, Priavali E, Gartzonika C et al. An eternal microbe: Brucella DNA load persists for years after clinical cure. CID 2008; 46: 131-6.

29. Elshamy M, Ahmed A. The effects of maternal brucellosis on pregnancy outcome. J Infect Developing Countries 2008; 2(3): 230-34.

30. Sauret JM, Vilissova N. Human brucellosis. J Am Board Fam Pract 2002; 15(5): 401-6.

31. Figueroa R, Rojas L, Marcano ES. Brucellosis in pregnancy: course and perinatal results. Gynecol Obstet Mex 1995; 63: 190-5.

32. Ozbay K, Inanmis RA. Successful treatment of brucellosis in a twin pregnancy. Clin Exp Obstet Gynecol 2006; 33(1): 61-2.

33. Khan MY, Mah MW, Memish ZA. Brucellosis in a pregnant women. Clin Infect Dis 2001; 32(8): 1172-77.